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Pathophysiological response of the blood coagulation system in
acute glomerulonephritis. A new procedure, plasma fibrinogen
chromatography, has been utilized, together with other blood co-
agulation assays, to quantify fibrin formation in 43 children with
acute poststreptococcal glomerulonephritis (AGN) from the time
of hospitalization until recovery. During the prediuretic phase of
AGN, significant evidence for substantial increase in fibrin forma-
tion (intravascular coagulation) included gross increase in plasma
high molecular weight fibrinogen complexes (H MWFC), the devel-
opment of either hypo- or hyperfibrinogenemia and gross depres-
sion of coagulation factor XIII concentration and of alpha2-
macroglobulin concentration. During the diuretic phase of the
disease, these abnormalities regressed and evidence of enhanced
plasma fibrinolytic activity, documented by an increase in fibrino-
gen first derivative, was detected. Concomitantly, urinary excretion
of fibrin(ogen) degradation products (FDP) underwent substantial
increase. With disease recovery, which occurred in all children,
urinary FDP excretion ceased and alL coagulation findings norma-
lized.
Réponse physiopathologique du système de coagulation sanguin
dans Ia glomérulonephrite aiguë. Une nouvelle technique, Ia chro-
matographie du fibrinogene plasmatique, a été utilisée en même
temps que les autres examens de Ia coagulation afin de quantifier Ia
formation de fibrine chez 43 enfants atteints de glomerulonephrite
post-streptococcique (AGN) depuis Ic moment de l'hospitalisationjusqu'à guérison. Durant Ia phase pré-diurétique de l'AGN les
preuves d'une augmentation importante de Ia formation de fibrine
(coagulation intravasculaire) comprennent une augmentation dans
Ic plasma des complexes de fibrinogène de haut poids mokculaire
(HMWFC), l'apparition d'une hypo ou d'une hyperfibrinogè-
némie, Ia diminution importante de Ia concentration du facteur
XIII et de l'alpha-2-macroglobuline. Au cours de Ia phase diuré-
tique de Ia maladie ces anomalies régressent et Ia preuve de
l'augmentation de l'activité fibrinolytique du plasma est obtenue
par Ia constatation d'une augmentation du premier dérivé du fibr-
inogène. En méme temps l'excrétion urinaire des produits de dé-
gradation (FDP) de Ia fibrine (ou du fibrinogene) subit une aug-
mentation importante. Avec Ia guérison de Ia maladie, observée
chez tous ces enfants, l'excrétion urinaire de FDP cesse et Ia
coagulation devient normale.
Several techniques used to induce acute dissemi-
nated intravascular coagulation produce renal lesions
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histologically indistinguishable from those of chronic
glomerulonephritis [1, 2]. These and other studies [3,
4] have suggested that intrarenal fibrin deposition,
presumably consequent upon vascular damage or im-
mune complex formation, may be of pathological
significance in experimentally induced glomerulo-
nephritis.
A similar situation may pertain in patients with
glomerulonephritis, for laboratory evidence of in-
travascular coagulation has frequently been observed
[5—7] and has been correlated with biopsy evidence of
fibrin or fibrinoid material in glomeruli [5]. In addi-
tion, "fibrin(ogen) degradation products" (FDP)'
have been detected in the urine of patients with renal
disease, especially during phases of disease activity [6,
7], in contrast to other diseases associated with in-
travascular coagulation in which significant urinary
FDP excretion rarely occurs. However, the urinary
excretion of FDP in renal disease could result from
increased permeability of diseased glomeruli to FDP
or fibrinogen [8]. Thus, these studies do not establish
the significance of intrarenal fibrin deposition as a
factor influencing disease outcome.
In the present investigation, several methods, in-
cluding a relatively new procedure, plasma fibrinogen
chromatography [9, 10], were used to study the coag-
ulation system and to detect alteration of in vivo
fibrin formation rates in 43 children with acute
glomerulonephritis presumed to be secondary to a
streptococcal infection.
Serial studies were started as early as possible in
the disease course and were continued until recovery
had occurred. Evidence for intravascular coagu-
lation, presumably of intrarenal origin and some-
times of gross degree, was found early in the disease
1These moieties have also been termed FSP (fibrinolytic split prod-
ucts) or FR antigen.
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course, but this phenomenon was of limited duration
and was followed by enhanced fibrinolysis and excre-
tion of FDP in the urine. All children apparently
recovered completely and the blood coagulation sys-
tem findings returned to normal. Thus, evidence of
intravascular coagulation in patients with glomerulo-
nephritis does not preclude spontaneous and com-
plete recovery.
Patient populations
After obtaining informed consent from their par-
ents, blood and urine samples were obtained serially
from 43 children, aged 3 to 15 yr, hospitalized with
acute poststreptococcal glomerulonephritis (AGN).
The diagnosis of AGN was established by clinical
and laboratory findings, typical disease manifesta-
tions being scored as follows: proteinuria, 3; hema-
tuna, 3; red blood cell casts in the urine, 1; decreased
beta1-C globulin, 2; decreased glomerular filtration
rate (GFR), 2; hypertension, 2; edema, 1; oliguria, 1;
circulatory overload as assessed by chest roentgeno-
gram, 2; and preceding streptococcal infection, 3.
GFR was measured by inulin or creatinine clearance
and the presence of hypertension was determined
from normal blood pressure ranges established for
the pediatric age groups [1 1]. Preceding streptococcal
infection was considered to be present if at least two
of the following criteria were met: 1) a history of
preceding sore throat, 2) growth of streptococci from
the throat culture, 3) the presence of an elevated titer
in either antistreptolysin 0 or antihyaluronidase dur-
ing the first week of hospitalization with a subsequent
change of titer. The presence of all the typical fea-
tures of AGN resulted in a diagnostic score of 20
points. Patients with scores of < 12 points were not
included in this study.
Of the 43 patients studied, 13 were scored at 18
points or higher, 21 at 15 to 17 points and 9 at 12 to
14 points. Thirty-nine of the patients fulfilled the
criteria for preceding streptococcal infection. None
of the patients had evidence of any systemic disease
known to be associated with glomerulonephritis. In
14 children, three of whom gave a history of a pre-
vious episode of AGN, the diagnosis was confirmed
by percutaneous renal biopsy.
The disease course was divided arbitrarily into sev-
eral phases. The acute phase was considered to last
from the time of the first clinical evidence of AGN
until the day the patient began to diurese, or in the
absence of edema, until the serum urea nitrogen and
creatinine concentrations began to decline. The phase
of resolution was divided into the initial five days, the
second five days and the remaining period until re-
covery. Recovery from AGN was considered corn-
plete when renal function had returned to normal and
the urine had been protein-free with a normal sedi-
ment for at least one month. Using these criteria, all
43 patients showed complete recovery. Proteinuria
rarely persisted for longer than one month after
diuresis, but microscopic hematuria persisted for an
average of 6.5 (range, 1 to 25) months. Renal biopsy
was not performed after recovery in any patient to
establish disease resolution.
Methods
Blood, 9 ml, was anticoagulated with I ml of 3.8%
sodium citrate containing 0.1 ml of 1 M epsilon ami-
nocaproic acid (EACA); plasma was separated by ten
minutes' centrifugation at 3,000 X g and kept frozen
at —20°C until assayed.
Plasma fibrinogen chromatography [9, 10] was used
to detect alteration in in vivo fibrin formation rates
(intravascular coagulation). This technique quan-
tifies the following classes of fibrinogen/fibrin-de-
rived moieties present in plasma; high molecular
weight fibrinogen complexes (4 X l0 to I X 108
daltons), referred to subsequently as HMWFC, na-
tive fibrinogen (3.4 X 108 daltons) and fibrinogen
derivatives of lower molecular weight than fibrinogen
(2.6 X 108 daltons or lower) subsequently described
as fibrinogen first derivative.
There is substantial biochemical evidence (12) that
plasma HMWFC elevation develops (a) with activa-
tion of the blood coagulation system, (b) with activa-
tion of both the blood coagulation and plasma fi-
brinolytic enzyme systems and (c) when fibrin is lysed
in plasma by the actions f the plasma fibrinolytic
enzyme system. While plasma HMWFC composition
will vary with the biochemical mechanism involved,
the common inciting pathway in all instances is the
formation of fibrin monomer and, consequently,
plasma HMWFC concentration reflects the overall
rate of fibrin formation in vivo.
There is also substantial clinical investigative evi-
dence [13, 14] that the finding of plasma high molecu-
lar weight fibrinogen complex (HMWFC) values in
excess of mean +2 SD of normal is significantly asso-
ciated with the presence of a thrombus, intravascular
fibrin deposition or, more rarely, with extravascular
fibrin deposition. Increase in the proportion or con-
centration of fibrinogen first derivative [15], some-
times termed fragment X, a proteolytic degradation
product of native fibrinogen is indicative of enhanced
thrombolytic activity.
Fibrinogen chromatography was performed as pre-
viously described [9, 10, 16] on Bio-Gel 5 M (Bio-
Rad, Richmond, CA). Two procedures were used:
Initially, samples were chromatographed on a 60 X
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0.9 cm column, 1 ml of plasma sample was applied
and effluent fraction assay was by radial immunodif-
fusion [9]. Later, samples were chromatographed on
a 30 X 2.5 cm column and packed with Bio-Gel SM
and 6-mm glass beads and effluent fraction analysis
was performed in the Technicon immunoprecipitator
(Technicon Corp., Tarrytown, NY) using mono-
specific (absorbed) human fibrinogen antiserum
(Gateway Serum Co., Cahokia, IL) equivalent to 4
mg of fibrinogen/rnl as determined by precipitin as-
say [14]. Chromatographic data were analyzed by a
computer program (Wang Laboratory Users Society,
Program M 7-7.5, Tewksbury, MA) based on
chromatographic plate theory [16] which was solved
for the relative percentage and concentration
(mg/100 ml) of HMWFC, native fibrinogen and fi-
brinogen first derivative.
Radial immunodiffusion. Plasminogen, alpha1-an-
titrypsin, alpha2-macroglobulin and antithrombin III
were determined by radial immunodiffusion using
antisera from Behring Diagnostics, Summerville, NJ
for the first three and antiserum from Nyegaard,
Oslo, Norway, for the last. Agarose plates (Sea-Kern
Marine Colloids, Springfield, NJ) were used. The
buffer contained 2 g of sodium ethylene diamine
tetraacetate (EDTA), 6 g of NaC1, 1.31 g of EACA,
1.2 g of tris hydroxymethyl aminomethane (THAM)
and 200 rng of sodium azide/liter adjusted to pH
7.4. Agarose, 1%, was solubilized at 100°C and the
solution was cooled to 56°C before the addition of
antiserum to a final concentration of 1 to 2%. Ten-
milliliter aliquots were poured into square disposable
Petri dishes and placed on a level surface and, after
cooling, 2-mm diameter holes were punched and 3-gil
sample aliquots were applied. A control plasma,
pooled from four normal individuals and kept frozen
in small aliquots, was applied to every seventh well.
All plasma samples were diluted 1:10 or 1:30 prior to
assay. After 48 hr, the precipitin zones were measured
on an antibiotic zone reader (Lilly, Fisher Scientific
Co.); if the zones were faint, they were developed by a
1% tannic acid wash. A plot of concentration against
zone area yielded a linear response [17] and the
coefficient of assay variation was 8%. Results have
been expressed as a percentage of normal values.
Other assays. Fibrinogen was determined by the
Ratnoff and Menzie procedure [18], coagulation fac-
tor XIII was determined by the method of Lorand et
al [19] with minor modification [20]. Plasminogen
was also determined by caseinolytic assay.
Fibrin(ogen) degradation products (FDP) were as-
sayed in urine after its dialysis and centrifugation,
using an immunoprecipitator (Technicon); data are
expressed as mg fibrinogen antigen equivalents ex-
creted/24 hr and the sensitivity of the procedure was
approximately 1 g/ml.
Data analysis. Laboratory data obtained from
patients after disease recovery have been treated as
"control" data. An additional group of 17 children
admitted to hospital for investigation, but in whom
the presence of significant disease was excluded, have
also been studied as control patients; these are re-
ferred to subsequently as the "hospitalized" group.
There were no significant differences in laboratory
findings between the children who had recovered
from AGN and the "hospitalized" control group,
except that alpha1-antitrypsin concentration was
higher in the hospitalized group (P < 0.01). Con-
sequently, except for comparison between alpha1-an-
titrypsin values, we have combined data from the
"recovered" and "hospitalized" groups to form a
single combined control group. Control laboratory
values, except for previously described age-related
differences in alpha2-macroglobulin concentration,
were similar, P > 0.1, to those found in healthy
adults.
Standard statistical methods have been used [211,
observational dispersion being expressed as the SEM
unless otherwise stated.
Results
Figure 1 displays serial plasma fibrinogen chroma-
tographic findings in a 3-yr-old girl with AGN. The
findings obtained on September 25 are representative
of the six studies performed during the first ten days
in hospital. This chromatogram was grossly abnor-
mal. There was a large inhomogeneous peak eluted
prior to native fibrinogen, comprising high molecular
weight fibrinogen complexes (HMWFC) with com-
puter analysis showing 36% HMWFC, 40% native
fibrinogen and 24% fibrinogen first derivative. The
value for HMWFC (36%) greatly exceeded mean + 2
SD of normal values (20% HMWFC). By October 4,
middle panel, HMWFC concentration was reduced
to 22% but its presence was still evident as a shoulder
on the ascending limb of the elution pattern. Eleven
days later, lower panel, HMWFC elevation was no
longer evident but, instead, the chromatographic pat-
tern was shifted to the right of the normal pattern
shown in the bottom panel of Figure 1. This
phenomenon was due to the presence of fibrinogen
derivatives smaller than native fibrinogen in the
patient sample (48%), compared to 24% in the con-
trol.
Serial data from three representative patients are
presented in Fig. 2, where the plasma fibrinogen
chromatographic findings are given in computer ana-
lyzed form. Patient 1 had minor laboratory abnor-
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were only mildly elevated and did not exceed mean +
2 SD of normal. Fibrinogen first derivative was within
the normal range until the third hospital day, when
there was an abrupt increase to a higher level, which
was maintained over the next week. Diuress oc-
curred shortly after admission and FDP was demon-
strated in the urine at this time and later.
The second patient, an 8-yr-old girl (second panel,
Fig. 2) was admitted to hospital with a history of
disease onset 24 hr earlier. Blood pressure was ele-
vated to a maximum of 160/130 mm Hg, serum urea
nitrogen to 52 mg/100 ml and serum creatinine to 1.4
mg/l00 ml with a GFR reduced to 21 ml/min/l.73
m2. Plasma HMWFC were elevated for the first four
days in hospital. Fibrinogen first derivative was nor-
mal initially, but increased sharply on the second
hospital day. Urine samples were obtained at the time
of diuresis and during the remainder of her hospital
stay: peak urinary excretion of FDP occurred on the
third and fourth days of diuresis. The plasma fibrino-
gen concentration fell during the acute disease phase
from 290 to 200 mg/100 ml over four days and then
slowly increased over the next five days to 350
mg/lOO ml.
Patient 3 (right-hand panel, Fig. 2) was the 3-yr-
old girl whose serial plasma fibrinogen chromato-
graphic findings are shown in Fig. 1. When admitted
to hospital, she was edematous, had a blood pressure
of 160/120 mm Hg, a serum urea nitrogen concentra-
tion of 38 mg/l00 ml and a GFR of 60 ml/min/l.73
m2. During the first ten days in hospital, plasma
HMWFC was substantially elevated, the plasma fi-
brinogen concentration was depressed and fibrinogen
first derivative was normal. Subsequently, plasma
HMWFC declined and GFR increased to 78
ml/min/l.73 m2 with a concomitant increase in fi-
Sept. 25 I
mality; patient 2, findings approximating the mean
for the group; and patient 3, laboratory abnor-
malities quantitatively greater and of longer duration
than those seen in the majority of patients.
The first patient, a 6-yr-old girl, was admitted to
hospital with a four-day history of edema, having had
a sore throat three weeks earlier. Initial blood pres-
sure (BP) was 130/80 mm Hg; glomerular filtration
rate (GFR), 42 ml/min/l.73 m2; serum urea nitro-
gen, 42 mg/lOO ml; and serum creatinine, 1 mg/lOO
ml. On admission (left-hand panel, Fig. 2), HMWFC
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Oct. 15 Fig. 1. Representative fibrinogen chromatographic findings in apatient with acute glomerulonephritis. Plasma samples were ob-
tained for analysis during the acute phase of the disease (top panel),
at the commencement of diuresis (middle panel) and during diuresis
(bottom panel). Each panel shows fibrinogen antigen concentration
as the ordinate and chromatographic effluent volume as the ab-
scissa. Column peak elution volume (V,) for native fibrinogen is
shown by the vertical interrupted line in all panels, and a typical
normal plasma fibrinogen chromatogram, open circles and inter-
rupted lines, is shown in the lowest panel for comparison purposes.
This normal chromatogram has a narrow elution pattern centered
around the Ve fibrinogen line; computer analysis of this pattern
showed a normal distribution for antigenically reactive "fibrino-
gen" of 7% HMWFC, 68% native fibrinogen and 25% fibrinogen
first derivative. All three chromatograms from this patient are
outside the physiologic limits: the top and middle chromatograms,
because of the presence of peaks to the left of the fibrinogen V line
demonstrating the presence of increased HMWFC, the bottom
chromatogram, because of the shift to the right of the V line
demonstrating the presence of an increased concentration of fi-
brinogen first derivative (see text).
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brinogen first derivative to 48% three weeks after
admission. Urinary FDP values were either zero or
low until plasma HMWFC fell below 20%, their ex-
cretion peaking 11 days after onset of diuresis.
Not all patients showed the same sequential pat-
tern of laboratory findings. Figure 3 depicts the find-
ings in two patients in whom plasma HMWFC were
elevated on admission, returned to within the normal
range but subsequently underwent further transient
elevation. In patient 4, the initial fall in plasma
HMWFC was associated with a fall in fibrinogen, a
reduction in blood urea nitrogen (BUN) concentra-
tion and elevation of urinary FDP excretion. How-
ever, following substantial elevation of plasma
HMWFC, on day 9, both fibrinogen and the BUN
rose sharply. Plasma fibrinogen first derivative con-
centration doubled. Possibly because of this in-
creased thrombolytic activity, plasma HMWFC val-
ues, plasma fibrinogen and BUN returned to normal
over the next three days with GFR rising from an
admission value of 19 to 58 ml/min/l.73 m2 after 16
days' hospitalization.
In patient 5, there was initial rapid decline in
plasma HMWFC, a fall in fibrinogen and an increase
in urinary FDP excretion. However, on days 12 and
17, the concentration of plasma HMWFC rose to
pathologic levels, but in this patient, fibrinogen first
derivative did not increase and GFR fell from an
admission value of 43 to 28 ml/min/l.73 m2 over this
period. Subsequently, plasma HMWFC again de-
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Fig. 2. Serial values for plasma fibrinogen (top panel), HM WFC percentage (second panel), fibrinogen
first derivative percentage (third panel) and urinary FDP excretion in mg/day (bottom panel) for
three patients. Laboratory abnormalities in patient I were relatively mild, findings in patient 2 were
approximate to the mean in the group, while findings in patient 3 were quantitatively greater and
of longer duration than those seen in the majority of patients (see text). The letter D with an arrow in the
bottom panel designates in each case the day of commencement of diuresis.
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Fig. 3. Serial findings in two patients in whom plasma HMWFC
normalized within three days of initial hospitalization, but later rose
to pathologic levels. In patient 4, fibrinogen first derivative rose
sharply at the time of plasma HMWFC increase, denoting en-
hanced plasma fibrinolysis, but this response was not detected in
patient 5 (right-hand panel of the diagram). GFR rose in patient 4
from 19 to 58 mI/min/l.73 m2 during this time, but in patient 5, it
decreased from an admission value of 43 to 28 ml/min/1.73 m2.
dined and the GFR rose to 78 ml/min/l.73 m2 one
month later.
Plasma fibrinogen chromatographic findings. Table
1 summarizes plasma fibrinogen and plasma fibrino-
gen chromatographic findings at various disease
stages. During the acute phase of AGN, concentra-
tions of plasma fibrinogen frequently were outside
the normal range, both high and low values being
observed. Thus, while mean plasma fibrinogen values
did not differ significantly from normal, their vari-
ance was significantly greater than that of the control
group (F = 1.51, P < 0.025).
Values for HMWFC were significantly increased
over control values (P < 0.001) when expressed either
as percentage or concentration. Values for plasma
HMWFC exceeding mean + 2 SD of normal were
found in 31 children during the acute disease phase
and these plasma samples tended to show fibrinogen
values below normal. The remaining children with
lesser elevation of plasma HMWFC often had milder
forms of disease or were first seen just prior to the
onset of diuresis; early peaking of plasma fibrinogen
was frequently seen in these patients. For example, in
four such patients in whom four or more early sam-
ples were available, serial fibrinogen values were as
follows: acute phase 406 51 mg/l00 ml; days 1
through 5 postdiuretic, 378 17 mg/lOO ml; and
days 6 through 10, 355 38 mg/100 ml.
With the onset of diuresis, the plasma fibrinogen
concentration rose significantly above control values
(P < 0.01) before returning to normal. Although
plasma HMWFC declined, values remained signifi-
cantly elevated (P < 0.02) during days 1 through 5,
but were normal by days 6 through 10. Fibrinogen
first derivative increased above control values during
days 1 through 5 after onset of diuresis and rose
higher during the subsequent five days.
Observations from the late recovery period (ten
days) mainly represent findings from children with a
more prolonged course. The only significant devia-
tion from the control values was minor elevation of
plasma HMWFC (P < 0.02).
Findings in the children after recovery did not
differ significantly from those obtained from the hos-
pitalized control group.
Other plasma proteins related to hemostasis. Coagu-
lation factor XIII (fibrin stabilizing factor) and plas-
minogen concentrations are shown in Table 2, which
also contains data on several inhibitors of blood co-
agulation and fibrinolysis, namely antithrombin III,
alpha2-macroglobulin and alpha1-antitrypsin.
Fifty-eight factor XIII assays on the children with
AGN were compared with ten values from the con-
trols; these control values in children were similar to
those in normal adults [20]. During the acute disease
phase, mean factor XIII concentration was signifi-
cantly depressed to 18.9 U/mI (P < 0.001). With the
onset of diuresis, these values increased to a mean of
23.7 U/mI, a figure which did not differ significantly
from control, although the range of values in patients
was greater than normal. A further increase in factor
XIII concentration was noted over the next five days.
The lowest plasminogen values were associated
with low plasma fibrinogen values and were seen
during the late recovery phase (ten days), these sam-
ples being obtained mainly from those patients with a
prolonged disease course. However, mean plasmino-
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Table 1. Fibrinogen concentrations and chromatographic findings at various stages of the disease and in controls
HMWFC Fibrinogen first derivative
Fibrinogen % of total % of total
N mg/lOOm! fibrinogen mg/lOOm! fibrinogen mg/lOOm!
Acute phase (prediuretic) 58 307 + 19 20.6 1•7b 64 + 6•7b 28.1 + 1.9 94 + 8.5
Days after onset of diuresis
0—5 57 360 12.7c 11.8 1.5d 46 + 53e 31.3 + 2.3 106 + 8,8d
6—10 39 341 + 15.1" 9.6 1.3 29 3.8 36.2 3.1" 120 4.6c
>10 24 275 20.4 15.3 33e 34 9.0 33.6 2.4 94 7.1
"Recovered" 32 299 16 8.6 1.4 24 4.2 29.5 4.6 72 8.1
Combined control 54 298 13.1 7.8 0.9 24 3.3 26.4 2.9 69 7.9
Data are mean + SEM.
b p < 0.001.
P < 0.01.
"P < 0.05.
P < 0.02.
gen concentration did not differ significantly from and in the remaining samples, the concentration of
control values at any stage of the disease. fibrinogen antigen was much lower than that seen in
Although some antithrombin III concentrations the same patient during the diuretic phase. Peak ex-
tended to be low, mean values did not differ signifi- cretion of fibrinogen antigen in urine was observed
cantly at any disease stage. Alpha2-macroglobulin three to five days after onset of diuresis except in one
was significantly reduced from control values (P < patient, patient 3, in whom peak excretion occurred
0.001) during the acute phase of disease, but after after ten days (Fig. 2). The total amount of urinary
diuresis it rapidly rose to near normal levels. Alpha1- FDP excreted during the recovery phase ranged from
antitrypsin was elevated during all stages of the dis- 10 to 860 mg and showed no clear relationship with
ease with the highest value being observed in samples disease severity. However, the data showed a non-
from the acute phase (P < 0.001). There was a slow statistically significant trend for total FDP excretion
fall during later recovery, to increase with patient age and weight.
Urinary FDP excretion. Serial observations of
urinary FDP excretion were made in 14 patients with Discussion
random sampling in others. Detailed results from five The findings from the present study demonstrate
of these patients are shown in Figs. 2 and 3. Little or that during the acute phase of AGN, intravascular
no fibrinogen antigen was found in urine samples (presumably intrarenal) coagulation constitutes a sig-
obtained during the acute phase; of 34 samples as- nificant feature of disease pathophysiology. This evi-
sayed, 17 showed no detectable fibrinogen (1g/ml), dence included the finding of increased levels of
Table 2. Coagulation factor XIII, plasminogen and inhibition data
Antithrombin Alpha2- Alpha,-
Factor XIII Plasminogen 111 macroglobulin antitrypsin
N" U/mi CTA U/mi % of normal % of normal % of normal
Acute phase (prediuretic) 40 18.9 1.05 2.20 0.07 97.1 + 3.2 74.2 + 2.2' 141.4 8.0"
N = 13
Days after onset of diuresis
0—5 48 23.7 1.71 2.26 0.06 101.1 2.6 94.8 2.3' 138.2 5.6'
N = 27
6—10 31 24.7 + 2.0 2.28 0.09 96.9 2.4 89.5 4.4 133.3 7.l'
>10 8 N = 11 2.05 0.56 101.1 8.3 83.4 5.9 127.3 + I 1.2'
"Recovered" 18 28.1 1.81 2.20 0.44 100 + 4.7 100 5.9 100 + 5.1
N=7
Combined control 32 27.0 + 1.54 2.22 0.09 101.1 3.4 96.4 5.3 Not used
N= 10 (see methods)
Data are mean + SEM.
b N refers to all assays except factor XIII where N values are listed in the columns.
P < 0.001.
"p <0.01.
P < 0.02.
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plasma HMWFC, alterations in plasma fibrinogen
concentration and reduction of both plasma factor
XIII and alpha2-macroglobulin concentration.
Plasma HMWFC formation results from activa-
tion of the blood coagulation system usually in asso-
ciation with activation of the plasma fibrinolytic en-
zyme system. Under physiologic conditions, the
plasma fibrinolytic enzyme system is partly activated
[22, 23] and the demonstration of elevated plasma
HMWFC with normal fibrinogen first derivative val-
ues during the acute phase of AGN would be consist-
ent with the interpretation that enhanced fibrin for-
mation was at least partially compensated for by
fibrinolysis. Although the mean concentration of
plasma fibrinogen was not abnormal in patients dur-
ing the acute phase of AGN, there was a significant
increase in assay variance confirmatory of the devel-
opment of hypo- or hyperfibrinogenemia. This obser-
vation supports the diagnosis of increased fibrin for-
mation, since these changes are similar to those
observed in animals given injections of thromboplas-
tic material to induce intravascular coagulation.
Large doses of thromboplastin induced hypofibrin-
ogenemia, but smaller doses, hyperfibrinogenemia
[24]. Coagulation factor XIII disappears during clott-
ing and fIbrin stabilization and its concentration in
serum is less than 5% of that present in the plasma
from which it was derived. Consequently, the finding
that plasma factor XIII concentration was signifi-
cantly depressed during the acute phase of disease
confirmed the existence of intravascular coagulation
and fibrin stabilization. Similarly, alpha2-macro-
globulin, an inhibitor of plasmin, thrombin and other
proteolytic enzymes, was significantly reduced, pre-
sumably because of activation of both the blood co-
agulation and plasma fibrinolytic enzyme systems.
Concomitantly, with clinical evidence of improve-
ment, e.g., the onset of diuresis, the coagulation sys-
tem findings altered. Plasma HMWFC fell, plasma
fibrinogen and fibrinogen first derivative increased
and factor XIII and alpha2-macroglobulin concentra-
tions both returned towards normal. These changes
were accompanied by increased urinary FDP excre-
tion which was of from three to seven days' duration
and which usually peaked approximately four days
after the patient began to diurese. These findings
demonstrate decreased fibrin formation and en-
hanced fibrinolysis. With clinical recovery, the coagu-
lation system findings returned to normal.
Our conclusion that a significant disturbance in
fibrinogen catabolism develops in patients with
glomerulonephritis is in apparent conflict with that of
George et al [25], who determined isotopically la-
belled platelet and fibrinogen survival in patients with
various types of glomerulonephritis. Because percent-
age decrease in platelet survival was of much greater
magnitude than percentage reduction in fibrinogen
survival, these investigators concluded that selective
platelet consumption was the lesion of major signifi-
cance and that disturbance of fibrinogen catabolism
was of minimal importance. This interpretation as-
sumes that fibrinogen survival is an efficient measure
of fibrin formation. However, under physiologic con-
ditions, fibrinogen to fibrin formation accounts for
only a small fraction of fibrinogen catabolism [26],
probably not exceeding 2 to 3% [27] and the SD for
fibrinogen survival determinations in normal subjects
is approximately 16% [26, 27]. Thus, a substantial
increase in the rate of fibrin formation could escape
detection by measurement of fibrinogen survival
alone. Indeed, since George et al reported that fibrin-
ogen survival may be reduced 10 to 20% in renal
disease, their results do not exclude a substantial
disturbance of fibrinogen catabolism in renal disease,
but rather suggest its occurrence.
Increased intravascular fibrin formation in AGN
may represent a nonspecific response to in-
flammation in the kidney. Injury to mammalian tis-
sue from whatever cause almost invariably elicits an
"inflammatory" response which includes swelling of
microcirculatory endothelium, vasodilatation, adhe-
sion of cells and platelets to endothelium, increase in
capillary permeability and fibrin deposition [28-30].
However, the ability of the kidney to recover from
such intrarenal fibrin formation is not surprising. In
animal models in which direct observation of the
vasculature is possible [28, 31], mechanical, thermal
and other insults to the capillaries result in local
platelet and fibrin deposition. These phenomena are
usually transient, local mechanisms presumably in-
volving activation of the plasminogen/plasmin en-
zyme system resulting in resolution of the lesion.
Thus, single or even multiple insults to capillaries
may result in transient, rather than permanent,
thrombotic occlusion, a condition with a high capac-
ity for spontaneous recovery on removal of the pre-
cipitating cause. Our data are in accord with this
hypothesis, for evidence of a significant degree of
enhanced fibrin formation, probably with com-
pensatory fibrinolysis, frequently persisted for days
prior to diuresis in the patients with AGN. With the
onset of diuresis, fibrinolysis predominated. That
fibrinolysis may occur in the glomeruli themselves is
suggested by the studies of Ekberg and Pandolfi [32].
These authors reported that while only 14 of 26 renal
biopsy specimens from patients with glomerulone-
phritis, studied by immunofluorescence, showed the
presence of material antigenically related to fibrin, 25
of 27 such biopsy specimens examined by the fibrin
slide technique showed substantially greater than
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normal fibrinolytic activity around the glomeruli and
small cortical vessels.
Our evidence demonstrates that intravascular, pre-
sumably intrarenal, coagulation occurring during the
acute phase of AGN does not prevent complete clini-
cal recovery. However, this conclusion does not ex-
clude a significant pathophysiologic role for in-
trarenal fibrin formation in AGN. While fibrin
deposition is a common response to injury or in-
flammation and may be regarded as a general body
repair mechanism, its effects may not always be bene-
ficial or appropriate to healing and may produce
reduction or cessation of blood flow in the affected
vessels. Thus, intraglomerular fibrin deposition, by
decreasing renal blood flow, may have contributed to
the decrease of GFR seen in the acute phase of AGN.
Under such circumstances, the use of anticoagulant
therapy could conceivably have resulted in a more
rapid return of GFR to normal than that seen in
untreated patients. The risks of such a therapeutic
approach probably outweigh the potential benefits in
a self-limited disease. Urinary excretion of FDP
peaked at the time of spontaneous clinical improve-
ment. Consequently, even the detection of high
urinary FDP would not constitute a logical in-
dication for anticoagulant therapy in AGN.
Intrarenal fibrin deposition was of limited duration
in our patient series and recovery occurred spontan-
eously. In contrast, we have observed patients with
glomerulonephritis who showed persistent evidence
of intravascular coagulation, renal biopsy evidence of
glomerular necrosis and crescent formation and who
had an unsatisfactory response to conservative ther-
apy. In this patient group, we interpreted evidence of
persistent intravascular coagulation as an indication
for anticoagulant therapy; all patients subsequently
improved (Robson AM, et al: Unpublished data).
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